Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3% – Here’s What Happened

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) traded down 6.3% during trading on Monday . The stock traded as low as $4.68 and last traded at $4.6650. 185,210 shares were traded during trading, a decline of 93% from the average session volume of 2,549,399 shares. The stock had previously closed at $4.98.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Citizens Jmp lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 5th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Taysha Gene Therapies Stock Up 2.9%

The firm has a market cap of $1.38 billion, a P/E ratio of -15.27 and a beta of 1.02. The firm’s fifty day moving average is $4.97 and its 200 day moving average is $3.93. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. As a group, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total value of $942,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at $4,740,327.69. The trade was a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 570,172 shares of company stock worth $2,637,906. Company insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of TSHA. AQR Capital Management LLC grew its stake in shares of Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after acquiring an additional 82,545 shares in the last quarter. Rhumbline Advisers boosted its holdings in Taysha Gene Therapies by 7.0% in the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after purchasing an additional 13,383 shares during the period. Chicago Partners Investment Group LLC grew its position in shares of Taysha Gene Therapies by 40.5% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 163,766 shares of the company’s stock worth $378,000 after purchasing an additional 47,201 shares in the last quarter. Ethic Inc. bought a new position in shares of Taysha Gene Therapies during the second quarter worth approximately $67,000. Finally, Tybourne Capital Management HK Ltd. increased its holdings in shares of Taysha Gene Therapies by 10.7% during the second quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after purchasing an additional 395,000 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.